Genetic toxicity tests currently used to identify and characterize potential human mutagens and carcinogens rely on measurements of primary DNA damage, gene mutation, and chromosome damage in vitro and in rodents. The International Life Sciences Institute Health and Environmental Sciences Institute (ILSI-HESI) Committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity Testing held an April 2012 Workshop in Washington, DC, to consider the impact of new understanding of biology and new technologies on the identification and characterization of genotoxic substances, and to identify new approaches to inform more accurate human risk assessment for genetic and carcinogenic effects. Workshop organizers and speakers were from industry, academe, and government. The Workshop focused on biological effects and technologies that would potentially yield the most useful information for evaluating human risk of genetic damage. Also addressed was the impact that improved understanding of biology and availability of new techniques might have on genetic toxicology practices. Workshop topics included (1) alternative experimental models to improve genetic toxicity testing, (2) Biomarkers of epigenetic changes and their applicability to genetic toxicology, and (3) new technologies and approaches. The ability of these new tests and technologies to be developed into tests to identify and characterize genotoxic agents; to serve as a bridge between in vitro and in vivo rodent, or preferably human, data; or to be used to provide dose response information for quantitative risk assessment was also addressed. A summary of the workshop and links to the scientific presentations are provided.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615680PMC
http://dx.doi.org/10.1002/em.21923DOI Listing

Publication Analysis

Top Keywords

genetic toxicology
12
genetic toxicity
12
genetic
8
identify characterize
8
sciences institute
8
toxicity testing
8
understanding biology
8
human risk
8
risk assessment
8
workshop
6

Similar Publications

Purpose: Reports of gene therapy-associated retinal atrophies and inflammation have highlighted the importance of preclinical safety assessments of adeno-associated virus (AAV) vector systems. We evaluated in nonhuman primates (NHPs) the ocular safety and toxicology of a novel AAV gene therapy targeting retinitis pigmentosa caused by mutations in PDE6A, which has since been used in a phase I/II clinical trial (NCT04611503).

Methods: A total of 34 healthy cynomolgus animals (Macaca fascicularis) were treated with subretinal injections of rAAV.

View Article and Find Full Text PDF

Objective: Heterocyclic amines (HCAs) are mutagens and carcinogens primarily generated when cooking meat at high temperatures or until well-done, and their major metabolic pathway includes hepatic N-hydroxylation via CYP1A2 followed by O-acetylation via N-acetyltransferase 2 (NAT2). NAT2 expresses a well-defined genetic polymorphism in humans resulting in rapid and slow acetylators. Recent epidemiological studies reported significant associations between dietary HCA exposure and insulin resistance and type II diabetes.

View Article and Find Full Text PDF

Background: Beedi rolling is a labor-intensive occupation that can cause a variety of health problems due to prolonged exposure to tobacco dust. This cross-sectional study aimed to assess morbidity, hematological profile, and DNA damage among beedi rollers in Karnataka.

Methods: A total of 153 participants, including 85 beedi and 65 non-beedi rollers, were enrolled in the study.

View Article and Find Full Text PDF

In Egypt, knowledge about vector-borne bacterial pathogens in camels remains limited. To address this gap, 181 blood samples from adult one-humped camels (Camelus dromedarius) in the greater Cairo metropolitan area were collected from October 2021 to March 2022. Through PCR assays, four pathogens were detected, where Anaplasmataceae being the most common (54.

View Article and Find Full Text PDF

Lower urinary tract symptoms (LUTS) significantly affect patient quality of life. Treatment options for bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH) (a common cause of LUTS) are insufficient to relieve discomfort. As the incidence of BPH is increasing, new pharmacological targets for LUTS treatment are required.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!